Clinical Trial: To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940336) titled 'To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy' on April 08.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Transthyretin Amyloid Polyneuropathy

Intervention: DRUG: Tafamidis Meglumine Soft Capsules

20 mg orally once daily for 72 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Qilu Pharmaceutical Co., Ltd...